---
DrugClass: "[[Adrenergic Blocking]]"
SubClass: "[[Antiadrenergic Drugs Centrally Acting]]"
DrugClassContra: "[[Adrenergic Blocking#Contraindications]]"
DrugClassAdverse: "[[Adrenergic Blocking#Side/Adverse Effects]]"
SecondaryDrugClass: "[[Antihypertensive Drugs]]"
SecondarySubClass: "[[Antiadrenergic Drugs Centrally Acting]]"
BrandName: Catapres, Catapres-TTS (transdermal), Kapvay
Chapter: "24"
KindleLinkChap: "[Chapter 24](kindle://book?action=open&asin=B09FRF11YJ&location=12809)"
KindleLink: 
tags:
  - Drug
  - Pharmacology
Course: Pharmacology
ChemLink: https://pubchem.ncbi.nlm.nih.gov/#query=
SecondaryAdverse: "[[Antihypertensive Drugs#Side/Adverse Effects]]"
SecondaryContra: "[[Antihypertensive Drugs#Contraindications]]"
ThirdDrugClass: "[[Central Nervous System Stimulants]]"
ThirdAdverse: "[[Central Nervous System Stimulants#Side/Adverse Effects]]"
ThirdContra: "[[Central Nervous System Stimulants#Contraindications]]"
SubCat: Miscellaneous Drugs
---
```smiles
C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
```

### Brand name
`=this.BrandName`
### Generic name
`= this.file.name`
### Drug class 
`= this.ThirdDrugClass`
	`= this.ThirdDrugClass.KindleLinkChap`
`= this.DrugClass`
	`= this.DrugClass.KindleLinkChap`
`= this.SecondaryDrugClass`
	`= this.SecondaryDrugClass.KindleLinkChap`

### Dosage & Usage
Hypertension, ADHD, severe pain in clients with cancer, opiate withdrawal (supervised only)
100– 600 µg/ day orally 
Transdermal: release rate 0.1– 0.3 mg/ 24 hr
0.4 mg/day (extended release only)

### Contraindications
See `= this.DrugClassContra`
See `= this.SecondaryContra`
See `= this.ThirdContra`
### Mechanisms of Action

### Side/Adverse Effects
See `= this.DrugClassAdverse`
See `= this.SecondaryAdverse`
See `= this.ThirdAdverse`
Drowsiness, dizziness, sedation, dry [[Mouth]], constipation, syncope, dreams, rash

### Interactions

`= this.ChemLink+this.file.name`

 